2018 was the year when the funding machine for privately held biotech companies went into overdrive, with mega-rounds and rapid flotations. John Hodgson brings us this deep dive.
Change history
18 June 2019
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Author information
Authors and Affiliations
Corresponding author
Integrated supplementary information
Supplementary Figure 1 Private biotech company exits.
a, Nasdaq Biotechnology Index (annual mean), 2009–2018. b, IPOs and M&As, 2010–2018. Source: Dow Jones VentureSource, Nasdaq.
Supplementary information
Supplementary Information
Supplementary Figure 1
Rights and permissions
About this article
Cite this article
Hodgson, J. Biotech’s baby boom. Nat Biotechnol 37, 502–512 (2019). https://doi.org/10.1038/s41587-019-0112-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-019-0112-4
- Springer Nature America, Inc.
This article is cited by
-
Translating academic careers into industry healthcare professions
Nature Biotechnology (2020)